Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer.

Wright JD, Ananth CV, Tsui J, Glied SA, Burke WM, Lu YS, Neugut AI, Herzog TJ, Hershman DL.

Cancer. 2014 Apr 15;120(8):1246-54. doi: 10.1002/cncr.28508. Epub 2014 Jan 17.

2.

Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer.

Vogel TJ, Goodman MT, Li AJ, Jeon CY.

Gynecol Oncol. 2017 Aug;146(2):340-345. doi: 10.1016/j.ygyno.2017.05.009. Epub 2017 Jun 7.

PMID:
28596017
3.

Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.

Bian C, Yao K, Li L, Yi T, Zhao X.

Arch Gynecol Obstet. 2016 Jan;293(1):163-8. doi: 10.1007/s00404-015-3813-z. Epub 2015 Jul 22.

PMID:
26198168
4.

Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.

Muraji M, Sudo T, Iwasaki S, Ueno S, Wakahashi S, Yamaguchi S, Fujiwara K, Nishimura R.

Gynecol Oncol. 2013 Dec;131(3):531-4. doi: 10.1016/j.ygyno.2013.09.030. Epub 2013 Oct 4.

PMID:
24096109
5.

Racial disparities in the treatment of advanced epithelial ovarian cancer.

Howell EA, Egorova N, Hayes MP, Wisnivesky J, Franco R, Bickell N.

Obstet Gynecol. 2013 Nov;122(5):1025-32. doi: 10.1097/AOG.0b013e3182a92011.

6.

Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?

Solmaz U, Mat E, Dereli ML, Turan V, Peker N, Tosun G, Dogan A, Adiyeke M, Ozdemir A, Gungorduk K, Sanci M, Yildirim Y.

J BUON. 2015 May-Jun;20(3):847-54.

PMID:
26214639
7.

Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database.

Rauh-Hain JA, Melamed A, Wright A, Gockley A, Clemmer JT, Schorge JO, Del Carmen MG, Keating NL.

JAMA Oncol. 2017 Jan 1;3(1):76-82. doi: 10.1001/jamaoncol.2016.4411.

8.

Ovarian Cancer Treatment and Survival Trends Among Women Older Than 65 Years of Age in the United States, 1995-2008.

Lin JJ, Egorova N, Franco R, Prasad-Hayes M, Bickell NA.

Obstet Gynecol. 2016 Jan;127(1):81-9. doi: 10.1097/AOG.0000000000001196.

9.

Sociodemographic disparities in advanced ovarian cancer survival and adherence to treatment guidelines.

Bristow RE, Chang J, Ziogas A, Campos B, Chavez LR, Anton-Culver H.

Obstet Gynecol. 2015 Apr;125(4):833-42. doi: 10.1097/AOG.0000000000000643.

10.

Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer.

Gockley A, Melamed A, Bregar AJ, Clemmer JT, Birrer M, Schorge JO, Del Carmen MG, Rauh-Hain JA.

Obstet Gynecol. 2017 Mar;129(3):439-447. doi: 10.1097/AOG.0000000000001867.

PMID:
28178043
11.

Costs of treatment for elderly women with advanced ovarian cancer in a Medicare population.

Forde GK, Chang J, Ziogas A, Tewari K, Bristow RE.

Gynecol Oncol. 2015 Jun;137(3):479-84. doi: 10.1016/j.ygyno.2015.03.050. Epub 2015 Apr 10.

PMID:
25866323
12.

Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer.

Thrall MM, Gray HJ, Symons RG, Weiss NS, Flum DR, Goff BA.

Gynecol Oncol. 2011 Dec;123(3):461-6. doi: 10.1016/j.ygyno.2011.08.030. Epub 2011 Sep 26.

13.

Ovarian cancer outcomes: Predictors of early death.

Urban RR, He H, Alfonso R, Hardesty MM, Gray HJ, Goff BA.

Gynecol Oncol. 2016 Mar;140(3):474-80. doi: 10.1016/j.ygyno.2015.12.021. Epub 2015 Dec 29.

PMID:
26743531
14.

Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer.

Chern JY, Curtin JP.

Curr Treat Options Oncol. 2016 Jan;17(1):1. doi: 10.1007/s11864-015-0380-2. Review.

PMID:
26714493
15.

[Treatment and prognostic factors for stage IV epithelial ovarian cancer].

Wu M, Shen K, Lang J.

Zhonghua Fu Chan Ke Za Zhi. 2000 Apr;35(4):200-3. Chinese.

PMID:
11776158
16.

Optimal primary surgical treatment for advanced epithelial ovarian cancer.

Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R.

Cochrane Database Syst Rev. 2011 Aug 10;(8):CD007565. doi: 10.1002/14651858.CD007565.pub2. Review.

PMID:
21833960
17.

Cost-Effectiveness of Neoadjuvant Chemotherapy versus Primary Surgery in Elderly Patients with Advanced Ovarian Cancer.

Poonawalla IB, Lairson DR, Chan W, Piller LB, Du XL.

Value Health. 2015 Jun;18(4):387-95. doi: 10.1016/j.jval.2015.01.005. Epub 2015 Mar 12.

18.

A SEER-Medicare analysis of the impact of metformin on overall survival in ovarian cancer.

Garcia C, Yao A, Camacho F, Balkrishnan R, Cantrell LA.

Gynecol Oncol. 2017 Aug;146(2):346-350. doi: 10.1016/j.ygyno.2017.05.006. Epub 2017 May 10.

PMID:
28499649
19.

Cost-utility comparison of neoadjuvant chemotherapy versus primary debulking surgery for treatment of advanced-stage ovarian cancer in patients 65 years old or older.

Rowland MR, Lesnock JL, Farris C, Kelley JL, Krivak TC.

Am J Obstet Gynecol. 2015 Jun;212(6):763.e1-8. doi: 10.1016/j.ajog.2015.01.053. Epub 2015 Jan 31.

PMID:
25644442
20.

Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer.

Rauh-Hain JA, Rodriguez N, Growdon WB, Goodman AK, Boruta DM 2nd, Horowitz NS, del Carmen MG, Schorge JO.

Ann Surg Oncol. 2012 Mar;19(3):959-65. doi: 10.1245/s10434-011-2100-x. Epub 2011 Oct 13.

PMID:
21994038

Supplemental Content

Support Center